In light of the ongoing threat posed by new viruses following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which led to the COVID-19 pandemic, new antiviral drugs ...

Investigators from Mass General Brigham have found that a method originally designed for cancer detection can also identify and monitor even tiny amounts of SARS-CoV-2 intact viral particles in blood ...

In a recent study published in the journal Nature, a group of researchers analyzed early cellular response dynamics to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in seronegative ...

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID-19 who have mild symptoms and face a high risk of hospitalization. For ...

Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19 ...

New research from The Wistar Institute's Salvino lab, led by professor Joseph Salvino, Ph.D., has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 ...

The global pandemic may be over, but SARS-CoV-2 continues to infect people around the world. Indeed, the United States has recorded roughly 750 deaths from COVID-19 over the past month. Now, an siRNA ...

Molecular and genomic testing in Native American patients with metastatic lung and colorectal cancers: A retrospective chart review. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...

New research has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and ...

ATLANTA — Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing ...